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Background: High frequency of loss of heterozygosity (LOH) was found at D7S486 in primary gastric cancer (GC).
And we found a high frequency of LOH region on 7q31 in primary GC from China, and identified D7S486 to be
the most frequent LOH locus. This study was aimed to determine what genes were affected by the LOH and
served as tumor suppressor genes (TSGs) in this region. Here, a high-throughput single nucleotide polymorphisms
(SNPs) microarray fabricated in-house was used to analyze the LOH status around D7S486 on 7q31 in 75 patients
with primary GC. Western blot, immunohistochemistry, and RT-PCR were used to assess the protein and mRNA
expression of TESTIN (TES) in 50 and 140 primary GC samples, respectively. MTS assay was used to investigate the
effect of TES overexpression on the proliferation of GC cell lines. Mutation and methylation analysis were
performed to explore possible mechanisms of TES inactivation in GC.
Results: LOH analysis discovered five candidate genes (ST7, FOXP2, MDFIC, TES and CAV1) whose frequencies of
LOH were higher than 30%. However, only TES showed the potential to be a TSG associated with GC. Among
140 pairs of GC samples, decreased TES mRNA level was found in 96 (68.6%) tumor tissues when compared with
matched non-tumor tissues (p < 0.001). Also, reduced TES protein level was detected in 36 (72.0%) of all 50 tumor
tissues by Western blot (p = 0.001). In addition, immunohistochemical staining result was in agreement with that
of RT-PCR and Western blot. Down regulation of TES was shown to be correlated with tumor differentiation
(p = 0.035) and prognosis (p = 0.035, log-rank test). Its overexpression inhibited the growth of three GC cell lines.
Hypermethylation of TES promoter was a frequent event in primary GC and GC cell lines. However, no specific
gene mutation was observed in the coding region of the TES gene.
Conclusions: Collectively, all results support the role of TES as a TSG in gastric carcinogenesis and that TES is
inactivated primarily by LOH and CpG island methylation.
Background
Gastric cancer (GC) is one of the leading causes of cancer
mortality in the world, particularly in East Asian coun-
tries such as China, Japan and Korea, as well as other
developing countries. Over the past decades, the overall
survival for GC has not significantly improved in spite of
improvement in surgical technique and significant
advancement of chemotherapy and radiotherapy options
[1]. Therefore, it is important to understand the molecu-
lar mechanisms involved in the carcinogenesis of GC.
Loss of heterozygosity (LOH) at specific sites of the
cancer genome is considered to embody tumor suppres-
sor genes (TSGs). Frequent LOH at 7q31.1/2 has been
detected in many human malignancies including GC [2].
Recently, we found a high frequency of LOH region on
7q31 in primary GC from China, and identified D7S486
to be the most frequent LOH locus [3]. This study was
designed to explore what TSGs associated with GC were
located around D7S486 in this region.
Using microarray technology, a high-throughput single
nucleotide polymorphisms (SNP) genotyping system was
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in 75 primary GC samples and to discover possible candi-
date genes. As a result, TESTIN (TES)s h o w e dt h ep o t e n t i a l
to be a TSG in GC after initial screening. To clarify its role
in GC, we examined TES expression in primary GC and its
relationship to clinicopathological characteristics and prog-
nosis. We also examined the effect of TES overexpression
on the proliferation of several GC cell lines. Furthermore,
mutation and methylation analysis were performed to
explore its possible mechanisms of inactivation in GC.
Results
Identification of candidate tumor suppressor genes
around D7S486 in primary GC
In this study, 75 pairs of DNA samples of tumor tissue
and matched adjacent non-tumor tissue obtained by
microdissection were extracted from patients with pri-
mary GC. For details of the result of microarray, please
see Additional file 1 and Additional file 2.
Based on the NCBI database, there were total of 21
identified genes and 14 expressed sequence tags (EST)
in the 4 Mb region (from 113 Mb to 117.5 Mb, please
see figure S1, Additional file 3) around D7S486. 347
SNPs were selected in this region, including 254 SNPs
located within genes and 93 SNPs located within ESTs.
PCR primers and probes of these SNPs were designed
by the previously described software [4]. After selection
by pretesting amplification, 309 optimal primer pairs
were determined (For ID of 309 SNPs, please see Addi-
tional file 4). Multiplex amplification was performed as
described in the Methods section. After hybridization
and genotype determination, 12 SNPs showed a fre-
quency of LOH > 15%. Further, 6 of 12 SNPs displayed
a frequency of LOH > 30% (Fig. 1 and Table 1) within 5
separate identified genes: FOXP2, ST7, MDFIC, CAV1
and TES. Among them, only ST7 [5], CAV1 [6] and TES
[7-11] have been reported to be candidate tumor sup-
pressor genes. However, little evidence supported ST7
and CAV1 to be tumor suppressor genes in primary GC.
In addition, we used RT-PCR to detect the mRNA level
of these candidate genes in 10 paired primary gastric
cancer tissues and matched non-tumor tissues, respec-
tively. And the results illustrated that TES mRNA
expression was significantly down regulated in primary
gastric cancer tissues than in non-tumor tissues, while
other genes failed to show such a significant difference
(please see figure S2, Additional file 5). Combining the
above results in this paper with the evidence from pre-
vious studies, TES shows great potential to be a candi-
date TSG associated with GC.
TES Expression in GC tissues
Among 140 pairs of GC samples, decreased TES mRNA
level was found in 96 (68.6%) tumor tissues when
compared with matched non-tumor tissues (p < 0.001,
Fig. 2A). Also, reduced TES protein level was detected
in 36 (72.0%) of all 50 tumor tissues by western-blot in
this study (p = 0.001, Fig. 2B). In addition, immunohis-
tochemical staining result was in agreement with that of
RT-PCR and Western blot. In all 140 paired GC sam-
ples, 32 (22.9%) cases displayed positive staining, pri-
marily in the cytoplasm of the cells within the tumor
tissues, while 120 (85.7%) cases exhibited positive stain-
ing in non-tumor tissues (p <0 . 0 0 1 ,F i g .2 C ) .A l lo ft h e
results demonstrated a significant down regulation of
TES mRNA and protein expression in primary GC.
Relationship between TES protein expression and
clinicopathological characteristics and prognosis in GC
As shown in Table 2, deletion or reduced TES protein
expression was associated with tumor differentiation;
the lower the differentiation, the lower TES expression.
Figure 1 Representative results of microarray images from 3
primary GC samples by microdissection. “T” for tumor tissue and
“N” for matched adjacent non-tumor tissue. (Each probe was
printed twice and shown as neighboring spots. Spots in red and
green, homozygous; yellow, heterozygous; and dark, low signal
represented no signal or too low for genotype calls. White pane
represented LOH, which is homozygous in tumor tissue but
heterozygous in matched non-tumor tissue.)
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TES positivity rates between the different groups (p =
0.007). By spearman analysis, the correlation value
between TES expression and tumor differentiation was
0.178 (p = 0.035). However, TES expression failed to be
correlated with age, sex, tumor size, metastasis, lym-
phoma invasion, T stage and clinical stage (p > 0.05).
In addition, the mean survival time of TES-positive
patients was 42.5 ± 4.7 months and the median was
Table 1 SNPs with frequency of LOH > 30% detected in 75 paired tumor tissue and matched adjacent normal tissue
samples from GC patients
SNP ID LOH Informative Individuals LOH (%) Alleles Allele Position/Total length Heterozygosity (%) Gene Link Position in Gene
rs6980093 11 24 45.8 A/G 301/601 0.229 FOXP2 Intron
rs1881287 17 56 30.4 A/G 301/601 0.533 TES Intron
rs2594458 9 27 33.3 A/G 301/601 0.257 MDFIC Intron
rs193573 17 48 35.4 A/G 501/706 0.457 ST7 Intron
rs6466550 16 51 31.4 C/T 201/401 0.486 None –
rs6466587 14 46 30.4 A/G 301/601 0.438 CAV1 Intron
Figure 2 TES expression in primary GC. A. Representative results
of TES mRNA expression in primary GC by RT-PCR. B. Representative
results of TES protein expression in GC by Western blot. C.
Representative staining of TES in GC tissue by
immunohistochemistry (× 100). “T” and “N” represent tumor tissue
and matched adjacent non-tumor tissue, respectively. D.
Representative staining of TES in gastric non-tumor tissue (× 100).
Table 2 Relationship between TES protein expression and
clinicopathological variables in 140 cases of primary GC
Clinicopathological variables n
† TESTIN cases (%) p-Value
Positive Negative
Age (years) 0.384
<56 68 12 (17.5) 49 (80.3)
≥56 72 17 (23.6) 55 (76.4)
Gender 0.886
Female 45 9 (20.0) 36 (80.0)
Male 95 20 (21.1) 75 (78.9)
Tumor size (cm) 0.789
<5 61 12 (19.7) 49 (80.3)
≥5 79 17 (21.6) 62 (78.4)
T stage 0.441
T1 12 1 (8.3) 11 (91.7)
T2 17 2 (11.8) 15 (88.2)
T3 85 19 (22.4) 66 (77.6)
T4 26 7 (26.9) 19 (73.1)
N stage 0.520
N0 44 6 (13.6) 38 (86.4)
N1 42 9 (21.4) 33 (78.6)
N2 43 11 (25.6) 32 (74.4)
N3 11 3 (27.3) 8 (72.7)
M stage 0.997
M0 111 23 (20.7) 88 (79.3)
M1 29 6 (20.7) 23 (79.3)
Clinical stage 0.686
I 17 2 (11.8) 15 (88.2)
II 28 5 (17.9) 23 (82.1)
III 51 11 (21.6) 40 (78.4)
IV 44 11 (25.0) 33 (75.0)
Differentiation 0.007*
Well 3 2 (66.7) 1 (33.3)
Moderate 30 12 (40.0) 18 (60.0)
Poor 97 13 (13.4) 84 (86.6)
Undifferentiated 10 2 (20.0) 8 (80.0)
† Number of cases in each group.
* Statistically significant (p < 0.05).
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values were 32.6 ± 2.2 months and 25.0 ± 5.1 months in
TES-negative patients, respectively. Using Kaplan-Meier
curve assessment, we found that negative TES expres-
sion was a significant prognostic factor of poor overall
survival in GC patients (p = 0.035, log-rank test), indi-
cating that primary GC patients with positive TES
expression showed a significantly longer survival time
(Fig. 3).
Overexpression of TES and its effect on proliferation of
GC cells
By RT-PCR, higher expression of TES was detected in
all three cell lines transfected with pEGFP-C2/TES com-
pared to the cell lines transfected with the empty
pEGFP-C2 plasmid (Fig. 4A). MTS proliferation assay
showed that relative growth rate in all three pEGFP-C2/
TES-transfected cells were significantly lower than those
counterparts in pEGFP-C2-transfected cells (p < 0.01)
(Fig. 4B, C, D).
TES gene mutation analysis
To detect mutations of the TES gene, direct sequencing
of all 7 exons of the TES gene was performed in three
gastric cell lines and five cases of GC with rs1881287
LOH. No mutation was detected in exons 1, 2, 3 and 5.
However, in the HGC27 cell line, we detected a hetero-
zygous nucleotide change in codon 221 of TES tran-
s c r i p t1i ne x o n4 ,f r o mG C Ct oG T C ,w i t ha na m i n o
acid substitution from alanine to valine. We also
detected a heterozygous nucleotide change in codon 364
in exon 7 of HGC27 and SGC7901 cells, from CGG to
CGC, both encoding arginine, and a homozygous
change from CGG to CGC at the same codon in Case
60. We searched the NCBI SNP database and found
that all of the above mutation sites are in accordance
with the cSNP sites of the TES gene. Another heterozy-
gous point mutation was detected in codon 312 of exon
6 from Case 61, from GAG to GGG, with the amino
acid substitution from glutamic acid to glycine, but the
non-tumor tissue from the same case also showed the
same heterozygous point mutation. While the other
non-tumor counterparts did not show any evidence of
mutation.
Abnormal DNA methylation of TES promoter in GC
The mRNA and protein expressions of TES in MGC803,
HGC27 and SGC7901 GC cell lines were not detected
by RT-PCR and Western blot, respectively (Fig. 5A, B).
Methylation analysis revealed complete methylation in
MGC803 and HGC27 cells, while no methylation was
detected in SGC7901 cells (Fig. 5C). In addition, 30 pri-
mary GC samples without TES expression as deter-
mined by immunohistochemistry were selected for
methylation analysis in the promoter of TES gene.
Among them, 18 samples showed complete methylation
in the TES promoter, 4 with partial methylation and 8
were unmethylated (Fig. 5D).
5-Aza-2′-deoxycytidine (decitabine; DAC) is a pyri-
midine nucleoside analog that strongly inhibits DNA
methyltransferase activity and, as such, is one of the
strongest inhibitors of DNA methylation and is also an
effective antileukemic agent [12]. Since the GC cell
lines MGC803 and HGC27 displayed complete methy-
lation in the TES promoter, we further investigated the
effect of DAC on its methylation. Interesting, after
treated with DAC, the complete methylation status in
the TES promoter changed to partial methylation and
nonmethylation in MGC803 and HGC27 cells, respec-
tively (Fig. 5E). In addition, mRNA and protein level of
TES also changed from negative to positive in both
MGC803 and HGC27 cells after DAC treatment
(Fig. 5F, G) as determined by RT-PCR and Western
blot, respectively.
Discussion
In our previous studies [3,13,14], we found that the
frequency of LOH at D7S486 was as high as 30.36% in
primary GC tissues. We also found that most GC
patients with a high frequency of LOH at D7S486 were
in their middle to advanced clinical stage (stage III and
IV), and usually correlated with lymph node metastasis
[3,13,14]. Taken together, these results suggest that one
or more tumor suppressor genes associated with gastric
carcinomas might situate around D7S486.
Figure 3 Estimated overall survival according to the expression
of TES in 140 cases of primary GC (Kaplan-Meier method). The
expression of TES was classified as negative expression (n = 108)
and positive (n = 32) based on the immunohistochemical staining
results.
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ray fabricated in-house, we performed the SNP LOH
assay in 75 paired GC samples. These SNPs are located
within genes and ESTs around D7S486 and with a het-
erozygosity frequency greater than 0.1. As a result, 6
S N P sw i t haL O Hf r e q u e n c yo f>3 0 %w e r ei d e n t i f i e d .
After bioinformatics analysis, 5 corresponding identified
genes were determined, including ST7, FOXP2, MDFIC,
TES and CAV1. Among these genes, no reports have
shown any correlations between FOXP2 and MDFIC
and human malignancy. Although ST7 [5] and CAV1 [6]
have been reported to be candidate tumor suppressor in
several types of cancer, no direct evidences support
their relationship with gastric carcinogenesis [5,14-16].
However, many previous studies on TES [7-11,17] have
demonstrated that it may be a candidate TSG in human
cancers.
Human gene encoding TES was first identified by
Tatarelli et al. [9] and localized to the fragile site
FRA7G at 7q31.2. So far, down regulation of TES has
been reported in many types of human malignancies
[8,10]. In addition, a profound reduction in growth
potential was detected in different cancer cell lines in
which TES was overexpressed [9,11]. All these findings
suggest that TES may present a candidate tumor sup-
pressor gene. However, to date, there is no definitive
report regarding whether TES w o r k sa saT S Gi np r i -
mary GC.
One of the most notable features of TSG is the muta-
tion that may lead to gene inactivation, especially muta-
tion in exon. Missense mutation has been detected in
exons 3 and 5 of TES in the leukemic cell line CEM and
in the ovarian cancer cell line CAOV3 [10]. However,
no mutation was detected in these two exons in our
study. A heterozygous mutation at codon 221 in exon 4
of TES has been reported in the breast cancer cell line
MDA-MB 453 [9] and in head and neck squamous cell
carcinoma tissues [8]. Similarly, the same mutation in
exon 4 was also detected in HGC27 GC cells in this
study. And a sense point mutation was also found in
exon 7 of TES.H o w e v e r ,a l lt h ea b o v es u b s t i t u t i o n s
were in accordance with the cSNP sites of the TES
gene, which had already been recorded in the NCBI
SNP database, suggesting that they were not tumor-spe-
cific. Moreover, in exon 6, we found a new heterozygous
missense point mutation in a GC tissue sample.
Although it has not been reported, the same mutation
w a sa l s oo b s e r v e di nt h em a t c h e dn o n - t u m o rt i s s u e .
Figure 4 Overexpression of TES and its inhibitory effect on the proliferation of GC cells. Three GC cell lines used in this study were
MGC803, HGC27 and SGC7901. A. TES mRNA expression in GC cells 36 h after transfection. B-D. The inhibitory effect of TES overexpression on
the proliferation of GC cells sorted by flow cytometry for 7 consecutive days. This experiment is a representative of three independent
experiments.
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be a mechanism for TES inactivation in GC.
When LOH occurs in a gene, the expression of the
gene may be reduced. Therefore, we then investigated
the expression of TES in primary GC. As expected, both
transcriptional and translational level of TES were
reduced in primary GC tissues, which is consistent with
its expression level in other types of human tumors,
indicating that the deletion or down regulation of TES
might be involved in the occurrence and development
of GC. Furthermore, less differentiated tumors exhibited
lower TES expression, indicating a significant correlation
between TES expression and tumor differentiation. In
addition, patients with negative expression of TES had a
shorter life span than those with positive expression,
suggesting that the detection of TES expression might
be helpful to assess prognosis in GC. In this study, we
also found for the first time that the introduction of
TES caused a significant growth delay in three GC cell
lines. This result demonstrated the suppressor effect of
TES on GC cells, supporting the idea that TES functions
as a tumor suppressor gene in GC, at least in these
three cell lines.
However, the mechanism of down regulation of TES
expression in GC is not fully understood. Besides LOH
causing reduction of gene expression, hypermethy-
lation of CpG islands located in the promoter
region of a gene is also frequently correlated with its
Figure 5 DNA Methylation analysis of TES promoter in GC. TES mRNA (A) and protein (B) expression were significantly down regulated in
three GC cell lines (MGC803, HGC27 and SGC7901). Methylation analysis of TES promoter in three GC cell lines (C) and in 10 pairs of GC samples
(D). Complete methylation was shown in MGC803 and HGC27 cells and in most GC samples. After DAC treatment, the complete methylation of
TES promoter changed to partial methylation and nonmethylation in MGC803 and HGC27 cells, respectively (E). DAC treatment also reversed TES
mRNA (F) and protein (G) expression in MGC803 and HGC27 cells. “M”, “U” and"M-P"represent methylated CPG sequences, unmethylated CPG
sequences and a positive control for methylation, respectively. “-” and “+” represent before and after DAC treatment, respectively.
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alternative mechanism for the inactivation of TSG
[19]. Several teams have reported on the methylation
status of TES promoter in different tumor types.
T o b i a s[ 1 1 ]f o u n df r e q u e n tm e t h y l a t i o no ft h eC p G
islands at the 5′end of TES in 7 of 10 ovarian carcino-
mas and in all 30 tumor-derived cell lines tested, but
only discovered a frame-shift mutation in one allele of
a breast cancer cell line and polymorphisms in a num-
ber of samples. Tatarelli [10] found the TES promoter
was fully methylated in the majority of 46 tumor-
derived cell lines, and only 3 of 46 tumor-derived cell
lines showed partial methylation at the promoter of
TES gene. Similarly, no homozygous deletions or a
high frequency of convincing somatic mutations was
found within the coding region of TES in a total of 26
cancer cell lines. All of these data demonstrate that
TES is inactivated primarily by transcriptional silencing
resulting from CpG island methylation rather than
gene mutation.
In this study, looking at 30 primary GC samples with
reduced TES expression as determined by immuno-
chemistry, 18 samples were found to be completely
methylated at the promoter of TES, 4 partially methy-
lated and 8 were found to be unmethylated. In three GC
cell lines with an absence of TES expression, the
MGC803 and HGC27 cells displayed complete methyla-
tion at the TES promoter, while no methylation was
detected in SGC7901 cells. These results suggest that
the methylation of CpG in the TES promoter was a fre-
quent event in GC and might be involved in the inacti-
vation of TES.
In this study, we further investigated the effect of
DAC, a pyrimidine nucleoside analog that strongly inhi-
bits DNA methyltransferase activity by titrating out
DNA methyltransferase activity via a covalent trapping
mechanism, on MGC803 and HGC27 GC cell lines,
which showed complete methylation at the TES promo-
ter. Interestingly, after DAC treatment, the complete
methylation of TES promoter changed to partial methy-
lation and nonmethylation in MGC803 and HGC27
cells, respectively. The mRNA and protein level of TES
also changed from negative to positive in both MGC803
and HGC27 cells following DAC treatment. These find-
ings further confirm that methylation of TES promoter
plays an important role in TES down regulation in GC.
In conclusion, the present study provides novel and
definitive data to support the idea that TES may play an
important role in primary GC as a tumor suppressor,
and also conforms that, besides LOH, hypermethylation
in the promoter of the TES gene rather than gene muta-
tions contributes to its inactivation and to the progres-
sion of gastric carcinogenesis.
Methods
Loss of heterozygosity analysis of the genes around
D7S486 by SNP genotyping system
Patients and tissue specimens
75 paired fresh GC and matched adjacent non-tumor
tissue specimens were obtained from patients underwent
surgical resection but without any preoperative treat-
ment in the Sun Yat-sen University Cancer Center
between 2004 and 2005. The 75 patients included
54 males and 21 females with a median age of 60 years.
After surgical resection, the fresh tissues were immedi-
ately immersed in RNAlater (Ambion, USA) and stored
at 4°C overnight to allow thorough penetration of the
tissues, then frozen at -80°C until RNA and DNA
extraction. Both cancer and matched adjacent non-
tumor tissues not less than 2 cm away from the GC
patients were sampled, respectively, and confirmed by
pathological examination. The study was approved by
the Ethics Committee of Sun Yat-sen University Cancer
Center and informed consent was obtained from each
patient.
DNA extraction from microdissected GC tissue
DNA samples were extracted from 75 paired GC speci-
mens obtained by microdissection using TRIzol kit
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s protocol. The procedures for microdissection
were performed as previously described [20].
SNP genotyping and LOH analysis by microarray system
SNP Selection A computer program written for SNP
selection was used as previously described [4]. SNPs in
a 4 Mb region around D7S486 on human chromosome
7q were selected from the dbSNP database ftp://ftp.
ncbi.nih.gov/snp/organisms/human_9606/chr_rpts/
maintained by National Center for Biotechnology
Information (NCBI, Build 36.3). To ensure that the
selected SNPs were real and suitable for the multiplex
system, a series of criteria described before was used
for selection [21].
Design of primer and probe To select sequence frames
for primers, a computer program described [4] before
was used. Within a user-defined sequence range
around the polymorphic sites (150 bp in the present
study), the candidate sequence frames were first
selected according to a user-defined melting tempera-
ture range (55°C to 75°C in this application). To
minimize primer-primer interactions, further selection
was performed on qualified frames based on a series of
criteria described before [4].
Multiplex PCR and ssDNA preparation The proce-
dures for multiplex amplification were performed fol-
lowing the method of Wang et al. [4] with minor
modifications. In brief, the first multiplex PCR reaction
was performed in 25 μlo fP C Rm i xc o n t a i n i n g2 . 5μlo f
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8.3, 1.5 mM MgCl2,a n d1 0 0μg/ml gelatin), 0.5 μlo f
10 nM dNTPs, primer mix (300 nM each) for all SNPs
in the multiplex group, 5 units of HotStart Taq DNA
polymerase, and 200 ng of DNA. The PCR cycling con-
ditions were: 95°C (15 min) for 1 cycle, 94°C (40 sec),
55°C (2 min), ramping from 55°C to 72°C (5 min) for
40 cycles and a final extension of 72°C (10 min). ssDNA
was generated in both directions using the same condi-
tions for multiplex PCR with the following modifica-
tions: (1) 1.0 μl of product from the multiplex PCR was
used as templates, (2) only one primer (one of the pri-
mer-probes) for each SNP was used, and (3) 45 PCR
cycles were performed.
SNP genotype determination by microarray In the
SNP genotyping system [4] adopted in this paper, after
generating single-stranded DNAs (ssDNA), they were
hybridized to the probes on a microarray fabricated in-
house. The probes were designed in such a way that
their 3′ ends were adjacent to the polymorphic sites in
the hybridizing ssDNA. In this way, the probes could be
labeled with the commonly used single-base extension
method [22-24], during which single dideoxyribonucleo-
tides (ddNTPs) were added to the probe in an allele-
specific manner that was dependent on the hybridizing
allelic sequence(s). When the corresponding ddNTPs
were labeled with different fluorescent chromophores
(cyanine dyes, either Cy3 or C5, in our system), the alle-
lic state of the SNPs were determined by analyzing the
amount of incorporated fluorescence with the written
program “AccTyping” [25]. In addition, SNP genotypes
could be determined independently with the two DNA
strands as separate templates so that results from such
dual-probe analysis could be compared to ensure a high
degree of accuracy.
Expression of TES in primary GC samples and its
relationship to clinicopathological characteristics
140 paraffin-embedded GC samples were retrieved
according to the 1999-2001 surgical pathology files in
the Sun Yat-sen University Cancer Center, which
included the patients without pretreatment. The 140
patients included 95 males and 45 females with a med-
ian age of 56 years. All tissue blocks were cut into serial
4 μm thick sections. The histological types were
assigned according to WHO classification criteria.
Total RNA was extracted from 140 patients with pri-
mary GC using TRIzol solution (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s protocol, and
RNAse-free DNase I was used to remove DNA contami-
nation. Reverse transcription (RT) was performed with 2
μg total RNA using M-MLV Reverse transcriptase (Pro-
m e g a ,M a d i s o n ,W I ,U S A )t osynthesize first-strand
cDNA according to the manufacturer’s recommendation,
followed by cDNA amplification using the specific primer
set for TES and the GAPDH primer set used as an inter-
nal control. Primers used in this study were as follows:
5′-ACTGTGGCAGACATTACTGTGACA-3′ (sense) and
5′-GATAGCTATGGCTCGATACTTCTGGGTGC-3′
(antisense) for TES;5 ′-CGGGAAGCTTGTCAT-
CAATGG-3′ (sense) and 5′-G GCAGTGATGGCATG-
GACTG-3′ (antisense) for GAPDH,a n dt h e
corresponding PCR products were 440 bp and 358 bp,
respectively.
Western blot and immunohistochemistry analysis was
carried out as our previously described [16]. Primary
polyclonal antibody against TES (Santa Cruz, CA, USA)
w a su s e da t1 : 5 0 0a n d1 : 1 0 0d i l u t i o n sf o rW e s t e r nb l o t
and immunohistochemistry, respectively. As our pre-
viously described [16], the total TES immunohistochem-
ical staining score was calculated as the sum of the
percent positivity of stained tumor cells and the staining
intensity.
Overexpression of TES and its effect on proliferation
of GC cells
Three GC cell lines used in this study were MGC803,
SGC7901 and HGC27. All cell lines were obtained from
the Committee of Type Culture Collection of Chinese
Academy of Sciences (Shanghai, China) and preserved
in our lab, and grown in RPMI 1640 supplemented with
10% FBS (fetal bovine serum) and antibiotics (50 μg/ml
each of penicillin, streptomycin and gentamicin) at 37°C
in a humidified 5% CO2 atmosphere.
Plasmid pOTB7 containing full-length TES cDNA
were purchased from Invitrogen (Carlsbad, CA, USA).
The TES cDNA was amplified with the following pri-
mers: upstream 5′-GCAAGCTTCATGGACCTG-
GAAAAC-3′,d o w n s t r e a m5 ′-GCGGATCCCTAAGACA
TCCTCTT-3′.T h e1 2 8 3b pf u l ll e n g t hTES cDNA PCR
product was recovered with the QIAquick Gel Extrac-
tion Kit (Qiagen Inc., Valencia, CA). The TES cDNA
was first cloned into a pGEM-T and then into a pEGFP-
C2 vector to create the pEGFP-C2/TES eukaryotic
expressing vector in which the TES cDNA was fused
with the downstream of EGFP cDNA.
Three gastric cell lines were transfected with pEGFP-
C2/TES or empty pEGFP-C2 plasmid, respectively,
using LipofectamineTM 2000 reagent (Invitrogen, Carls-
bad, CA, USA) according to the manufacturer’s instruc-
tions. Briefly, cells were seeded into a 75 cm
2 culture
flask, and 12-24 μg plasmid and 36-60 μl Lipofectamine
2000 reagent were used for transfection when cells were
at 90% confluence. Cells were harvested 36 h after trans-
fection and tested in the proliferation assay or harvested
for RT-PCR detection.
Measurement of proliferation was determined by the
MTS assay. Briefly, GFP-positive cells were sorted 36 h
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into 96-well plates (1000 cells per well) in 100 μlR M P I
1640 medium for five replicates. The next day, after 20
μl CellTiter 96 Aqueous One Solution (Promega, Madi-
son, WI, USA) were added into the medium, the cells
were incubated at 37°C for 4 h, and the absorbance at
490 nm (OD490) was measured daily for 7 days.
Mutation analysis of TES gene
Each exon of TES was PCR amplified respectively. The
PCR mixture contained 1 μgg e n o m i cD N A ,2 0μl2×
Pfu PCR MasterMix (TIANGEN Biotech, Beijing, China)
and 0.1 pmol/μl of each primer in a total 40 μlv o l u m e .
The PCR cycling conditions for exons 2 to 7 were: 94°C
(2 min) for 1 cycle, 94°C (30 sec), 55°C (40 sec), 72°C
(2 min) for 40 cycles and a final extension of 72°C
(10 min). Exon 1 PCR conditions were as described
above with the exception that the initial denaturation
was performed at 97.6°C for 5 min, and the denatura-
tion temperature in the 40 cycles was also set at 97.6°C.
For identification of mutations, PCR products were puri-
fied and then sequenced on an ABI Prism 3700 auto-
mated DNA Analyzer. All mutations were confirmed by
sequencing in both directions.
Methylation analysis of TES promoter in primary GC
Three GC cell lines used in this study were MGC803,
SGC7901 and HGC27 with the same culture condition
as described above. 10 μM of 5-aza-2′-deoxycytidine
(decitabine; DAC) was added when cell density reached
75%. Culture medium was changed with fresh
RPMI1640 with the same concentration of DAC on
alternate days. PBS (10 μM) was used as a negative con-
trol. Cells were harvested for the experiment six days
later.
The genomic DNA isolated with the DNeasy Tissue
Kit (Qiagen Inc., Valencia, CA) was modified by bisulfite
treatment with the CpGenome DNA Modification Kit
(Chemicon) and amplified by PCR with two sets of TES
promoter specific primer pairs (M-TES sense 5′-TATT-
GAGTTTGTTTAGTAGGGCGTC-3′,M - TES antisense
5′-AATAACAACCGAACAACTCCG-3′,P C Rp r o d u c t
133 bp; U-TES sense 5′-TGAGTTTGTTTAG-
TAGGGTGTTG-3′,U - TES antisense 5′-ATAACAAC-
CAAACAACTCCAA-3′, PCR product 129 bp) that
recognize either the methylated or unmethylated CpG
sequences and then analyzed by electrophoresis.
Statistical analysis
Quantitative values were expressed as the means ± SD
or median (range). The Quantity One software (Bio-Rad
Laboratories, Inc. Hercules, CA, USA) was used to
quantify the densities of the bands in RT-PCR and Wes-
tern blot. Paired-samples t-test was used to compare
mRNA and protein expression of TES in GC with
paired adjacent non-tumor tissue samples. The c
2 test
for proportion and Spearman’s correlation was used to
analyze the relationship between TES expression and
various clinicopathological characteristics. Survival
curves were calculated using the Kaplan-Meier method
and compared by the log-rank test. The SPSS 15.0 soft-
ware (SPSS Inc., Chicago, IL, USA) was used for all sta-
tistical analyses and p < 0.05 was considered significant.
Additional material
Additional file 1: microarray data. SNP microarray result from 75
patients with primary GC.
Additional file 2: Patient information. Information of 75 patients in
SNP microarray assay.
Additional file 3: Figure S1 - Schematic figure. Schematic figure of
the 4 Mb region (from 113 Mb to 117.5 Mb) around D7S486.
Additional file 4: SNP ID. ID of 309 SNPs in microarray assay.
Additional file 5: Figure S2 - mRNA expression of 5 genes in
primary GC. Representative result of the mRNA expression levels of 5
genes, FOXP2, MDFIC, ST7, CAV1 and TES in primary GC by RT-PCR. “T”
and “N” represent tumor tissue and matched adjacent non-tumor t from
patients with primary GC issue, respectively.
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